On November 26, the State Food and Drug Administration announced that irbesartan hydrochlorothiazide tablets of Beijing Sihuan Kebao Pharmaceutical Co., Ltd. were approved!
The "one-stop" clinical research of this variety is completed by Duzheng Biology (the cooperative co construction unit Changsha Central Hospital is responsible for clinical, shetong intelligence is responsible for recruitment, Xianling medicine is responsible for SMO service, and Farmco data is responsible for data management and statistical analysis). The clinical and analysis of this product are free from on-site verification.
Irbesartan hydrochlorothiazide tablet is a compound preparation of angiotensin II receptor antagonist and thiazide diuretics, which has been included in the national centralized collection, 4 + 7 and expanded centralized collection varieties.
As a "one-stop" service platform for clinical research, Duzheng biology has helped a number of pharmaceutical enterprises to be successfully approved. After "July 22", the company has carried out more than 400 clinical studies, completed more than 300, approved the production of more than 30, and accepted the verification of the National Bureau and the Provincial Bureau for more than 70 times, with a pass rate of 100%.